Effect of Butorphanol on Colonoscopy for Patients With Postoperative Visceral Pain

Beijing Tiantan Hospital203 enrolled

Overview

The total incidence of abdominal pain after colonoscopy is almost 50%. Butorphanol is a mixed opioid receptor agonist-antagonist, which has strong sedative and analgesic effects. This clinical study aims to explore the effectiveness and safety of butorphanol combined with propofol for colonoscopy to reduce postoperative visceral pain, and provide a basis for improving the quality of surgery and comfortable medical treatment for patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

203

Conditions

Colonoscopy

Interventions

Butorphanol InjectionDRUG

Inject 10 μg/kg of butorphanol, then propofol is injected until the patient's eyelash reflex disappears before performing colonoscopy

SalineDRUG

Inject saline and propofol until the patient's eyelash reflex disappears before performing colonoscopy

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ASA status I-11 * patients performing colonoscopy * sign the informed consent Exclusion Criteria: * BMI\>30, pregnant * diabetes * depression * patients dependent on opioids * hypertension poorly controlled * serious complications of important organs * obvious abdominal pain before colonoscopy

Locations (1)

Beijing Tiantan Hospital

Beijing, China

Outcomes

Primary Outcomes

visceral pain

VAS score of visceral pain

Time frame: 10 minutes after recovery

Secondary Outcomes

visceral pain at 20 and 30 minutes after recovery

VAS score of visceral pain

Time frame: 20 and 30 minutes after recovery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.